Abstract:Objective Hyperphenylalaninemia (HPA) is a genetic disease with the higher blood phenylalanine (Phe) level caused by the phenylalanine hydroxylase deficiency or the lower enzyme activity. Phenylketonuria (PKU) is the most common type of HPA. In this paper, the authors reviewed the clinical diagnosis, treatment and gene mutation detection of HPA in order to set up a preventive and therapeutic method for the disease. Method Seven hundred and sixty-nine subjects (454 males and 315 females, aged 0.8—27 years) with HPA from 28 provinces of China were enrolled in this study. Among them, 95 patients were diagnosed by the neonatal screening, 50 diagnosed by the high risk screening, the other 624 patients were diagnosed later. The family histories of all patients were investigated. The Phe concentration was determined with Guthrie bacterial inhibition assay and fluorescence method. The tetrahydrobiopterin deficiency (BH4D) was examined with the urinay pterin analysis and BH4 loading test. PKU patients were treated with the low or free Phe formula. The patients with BH4D were treated with BH4 and neurotransmitter precursors. The effects of the clinical treatment in patients with various HPA types were evaluated. The PKU gene was detected for mutations in 100 PKU patients. Prenatal diagnosis was carried out for 23 families with high risk PKU by using denaturing gradient gel electrophoresis (DGGE) and STR linkage analysis. Result (1) Of 769 patients 730 were diagnosed as having classic PKU, 27 patients as mild HPA and, 12 patients as BH4D whose urinary percentage of biopterin was (1.74±2.6) %, which was below the normal range. (2) Three hundred and thirty-eight PKU cases were treated with low or no phenylalanine milk. Of 95 patients, 71.6% of patients was diagnosed by neontal screening and 54.7% of 243 patients diagnosed later and the Phe could be better controlled with the treatment. (3) The intelligence quotient (IQ) evaluation was performed in 112 treated patients. The IQ of 55 patients diagnosed and treated after the neonatal screening was (78±22) score, IQ of 57 patients diagnosed later was (62±18) score. The IQ scores of these two groups were significantly different(P<0.001). IQ score of five BH4D patients was 70—80 after the treatment with combination of BH4 and neurotransmitter precursors. (4) Seventy-two patients went to school and 66.7% of them showed a middle or higher study score. (5) Five mutations, Arg111Ter, Arg241Cys, Arg243Glu, IVS6nt-1 and Arg252Gln, as well as a polymorphism of Val245Val were found in 100 PKU cases. (6)Prenatal diagnosis was performed for 23 families with high risk PKU, three fetuses were found to have PKU, and 20 fetuses were normal or heterozygotes which was confirmed by the neonatal screening for PKU after birth. Conclusion Both prenatal diagnosis and early diagnosis are effective methods for prevention and treatment of PKU. The early treatment and restriction of Phe level can minimize the mental retardation for HPA patients. Key words: Phenylketonurias; Neonatal screening; Biopterin; Genes; Mutation

Results of neonatal screening for congenital hypothyroidism and hyperphenylalaninemia in Zhejiang province from 1999 to 2022

Neonatal screening for congenital hypothyroidism and phenylketonuria in China

Newborn Screening in Zhejiang, China

[Retrospective Study on Neonatal Screening for Congenital Hypothyroidism and Phenylketonuria in China in the Past 22 Years].

Screening for congenital hypothyroidism in neonates of Zhejiang Province during 1999-2004]

Screening for phenylketonuria in 726,998 neonates in Zhejiang Province]

Mutations in Patients with Hyperphenylalaninemia in Zhejiang, China

[Screening for Fatty Acid Oxidation Disorders of Newborns in Zhejiang Province:Prevalence, Outcome and Follow-Up].

Newborn screening in China: phenylketonuria, congenital hypothyroidism and expanded screening.

Pitfalls in the Management of Phenylketonuria in China

Diagnosis, Treatment and Long-Term Following Up of 223 Patients with Hyperphenylalaninemia Detected by Neonatal Screening Programs

Clinical analysis about 2 789cases of congenital hypothyroidism

Birth prevalence of tetrahydrobiopterin deficiency in China: data from the national newborn screening program, 2013-2019

Diagnosis, Treatment and Gene Detection in 769 Cases with Hyperphenylalaninemia

The molecular epidemiology of hyperphenylalaninemia in Uygur population: incidence from newborn screening and mutational spectra

Study on 398 Neonates with Various Types of Hyperphenylalaninemia Detected by Neonatal Screening Program and 26 Year-Experiences of Diagnosis and Treatment for Hyperphenylalaninemia

Demographics, diagnosis and treatment of 256 patients with tetrahydrobiopterin deficiency in mainland China: results of a retrospective, multicentre study

[The Investigation of Differential Diagnostic Development and Incidence of Tetrahydrobiopterin Deficiency].

Mutational and Phenotypic Spectrum of Phenylalanine Hydroxylase Deficiency in Zhejiang Province, China

Neonatal Screening for Congenital Hypothyroidism and Phenylketonuria in Chengdu from 1992 to 2010

Predictive value of fluorometric method and tandem mass spectrometry for hyperphenylalaninemia and its subtypes in China: A systematic review and meta‑analysis.